Profile data is unavailable for this security.
About the company
Koninklijke Philips N.V. is the Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.
- Revenue in EUR (TTM)19.49bn
- Net income in EUR1.05bn
- Incorporated2000
- Employees80.72k
- LocationRoyal PhilipsAmstelplein 2AMSTERDAM 1096 BCNetherlandsNLD
- Phone+31 205977777
- Fax+31 205977220
- Websitehttps://www.philips.com/
Mergers & acquisitions
| Acquired company | PHIA:AEX since announced | Transaction value |
|---|---|---|
| Medumo Inc | 7.24% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Carl Zeiss Meditec AG | 1.51bn | 165.59m | 8.27bn | 3.34k | 50.12 | 5.67 | -- | 5.49 | 1.85 | 1.85 | 16.80 | 16.32 | 0.767 | 2.21 | 8.77 | 466,294.60 | 8.48 | 8.17 | 10.21 | 10.44 | 56.84 | 54.77 | 11.06 | 9.71 | 3.12 | 14.04 | 0.0996 | 38.12 | 13.93 | 9.92 | 26.33 | 16.34 | 20.85 | 10.20 |
| Sonova Holding AG | 2.75bn | 454.92m | 12.14bn | 15.18k | 26.58 | 6.22 | 18.71 | 4.42 | 7.54 | 7.54 | 45.67 | 32.22 | 0.6645 | 3.04 | 6.46 | 192,103.50 | 11.15 | 10.91 | 14.82 | 13.69 | 71.43 | 69.92 | 16.78 | 16.10 | 0.8661 | 69.37 | 0.2978 | 31.83 | 5.56 | 7.47 | 6.41 | 6.06 | 7.68 | -- |
| Straumann Holding AG | 1.50bn | 288.54m | 12.85bn | 7.49k | 44.56 | 9.98 | 33.99 | 8.55 | 19.26 | 19.26 | 100.31 | 85.94 | 0.7504 | 1.88 | 4.73 | 213,000.40 | 14.48 | 15.64 | 18.15 | 18.58 | 75.47 | 76.14 | 19.30 | 20.20 | 1.12 | 14.91 | 0.1449 | 32.56 | 17.06 | 17.58 | 12.36 | 14.19 | 51.40 | 8.92 |
| Smith & Nephew plc | 4.56bn | 532.38m | 15.32bn | 17.64k | 28.82 | 3.35 | 15.75 | 3.36 | 0.5456 | 0.5456 | 4.67 | 4.69 | 0.592 | 0.8893 | 3.89 | 232,312.60 | 6.91 | 8.41 | 8.37 | 10.22 | 73.96 | 73.94 | 11.68 | 13.50 | 1.03 | 23.02 | 0.2848 | 45.92 | 4.77 | 2.16 | -9.50 | 3.67 | 1.70 | 5.98 |
| Sartorius Stedim Biotech SA | 1.52bn | 253.47m | 21.96bn | 6.20k | 87.00 | 17.90 | 65.88 | 14.45 | 2.74 | 2.74 | 16.42 | 13.31 | 0.8548 | 2.38 | 6.86 | 245,005.60 | 14.34 | 13.41 | 19.19 | 17.91 | 52.23 | 51.35 | 16.78 | 15.61 | 0.8388 | 34.46 | 0.0852 | 25.94 | 18.84 | 16.08 | 12.75 | 26.49 | 23.64 | 25.70 |
| Coloplast A/S | 2.52bn | 539.63m | 27.56bn | 12.00k | 54.97 | 33.51 | 43.02 | 10.95 | 18.86 | 18.86 | 87.99 | 30.94 | 1.45 | 3.16 | 5.88 | 1,553,089.00 | 31.14 | 27.20 | 55.55 | 47.22 | 68.13 | 67.96 | 21.44 | 19.82 | 0.8134 | 20.18 | 0.3249 | 100.87 | 9.06 | 7.62 | 0.7282 | 10.14 | 5.30 | 8.13 |
| Koninklijke Philips NV | 19.49bn | 1.05bn | 38.95bn | 80.72k | 37.55 | -- | 15.27 | 2.00 | 1.14 | 1.12 | 21.09 | -- | -- | -- | -- | 242,126.80 | -- | 3.18 | -- | 4.61 | 45.32 | 45.74 | 5.45 | 5.05 | -- | 16.73 | -- | -- | 7.51 | -1.85 | -8.98 | 39.44 | 3.67 | -- |
| Siemens Healthineers AG | 14.98bn | 1.56bn | 41.95bn | 53.00k | 26.98 | 4.36 | 18.22 | 2.80 | 1.55 | 1.55 | 14.93 | 9.62 | 0.7029 | 4.03 | 4.51 | 288,134.60 | 7.41 | -- | 10.03 | -- | 39.31 | -- | 10.55 | -- | 0.873 | 121.05 | 0.0508 | -- | 8.11 | -- | 23.87 | -- | -- | -- |
| EssilorLuxottica SA | 17.39bn | 1.08bn | 51.96bn | 151.24k | 48.61 | 1.49 | 15.59 | 2.99 | 2.44 | 2.44 | 39.42 | 79.52 | 0.3444 | 3.21 | 7.31 | 114,981.30 | 2.35 | 4.40 | 2.73 | 5.44 | 61.24 | 61.19 | 6.81 | 9.89 | 1.53 | 12.25 | 0.2104 | 35.08 | 60.53 | 25.12 | -0.554 | 3.00 | 31.23 | 16.93 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 May 2020 | 32.83m | 3.66% |
| Wellington Management Co. LLPas of 05 Jun 2020 | 22.99m | 2.56% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2020 | 18.55m | 2.07% |
| Norges Bank Investment Managementas of 31 Dec 2019 | 18.54m | 2.07% |
| BlackRock Investment Management LLCas of 25 Jun 2020 | 14.41m | 1.61% |
| Amundi Asset Management SA (Investment Management)as of 22 Jun 2020 | 14.28m | 1.59% |
| BlackRock Fund Advisorsas of 04 Jun 2020 | 12.43m | 1.39% |
| Fidelity Management & Research Co. LLCas of 30 Apr 2020 | 8.81m | 0.98% |
| T. Rowe Price International Ltd.as of 31 Mar 2020 | 8.80m | 0.98% |
| Capital Research & Management Co. (Global Investors)as of 31 Mar 2020 | 8.71m | 0.97% |
